Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies - PubMed (original) (raw)
Affiliations
- PMID: 16513609
Free article
Clinical Trial
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies
Lawrence M Cher et al. J Nucl Med. 2006 Mar.
Free article
Abstract
PET offers a noninvasive means to assess neoplasms, in view of its sensitivity and accuracy in staging tumors and potentially in monitoring treatment response. The aim of this study was to evaluate newly diagnosed primary brain tumors for the presence of hypoxia, as indicated by the uptake of 18F-fluoromisonidazole (18F-FMISO) and to examine the relationship of hypoxia to the uptake of 18F-FDG and molecular markers of hypoxia.
Methods: Seventeen patients with suspected primary glioma were enrolled prospectively in this study. Sixteen patients had histology, with 2 having metastatic disease. All patients had PET studies with 18F-FMISO and 18F-FDG and MRI studies. Immunohistochemistry was undertaken with tumor markers of angiogenesis and hypoxia. Patients were monitored for disease progression and statistical analysis of data was performed.
Results: Of the 14 patients with histology, 8 died with a median time of 16 mo (range, 2-30 mo) until death. Of those who died, 7 had positive and 1 had negative 18F-FMISO uptake. 18F-FMISO uptake was observed in all high-grade gliomas but not in low-grade gliomas. A significant relationship was found between 18F-FDG or 18F-FMISO uptake and expression of VEGF-R1 and Ki67 expression. Other immunohistochemical markers demonstrated a trend toward increased uptake but none was significant.
Conclusion: 18F-FMISO PET provides a noninvasive assessment of hypoxia in glioma and was prognostic for treatment outcomes in the majority of patients. 18F-FMISO PET may have a role not only in directing patients toward targeted hypoxic therapies but also in monitoring response to such therapies.
Similar articles
- Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder TH, O'Keefe GJ, Scott AM. Cherk MH, et al. J Nucl Med. 2006 Dec;47(12):1921-6. J Nucl Med. 2006. PMID: 17138734 - [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans JM, Levallet G, Bordji K, Petit E, Branger P, Emery E, Manrique A, Barré L, Bernaudin M, Guillamo JS. Bekaert L, et al. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1383-1392. doi: 10.1007/s00259-017-3677-5. Epub 2017 Mar 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 28315948 Clinical Trial. - Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, Maeda Y, Yamamoto Y, Nishiyama Y, Tamiya T. Kawai N, et al. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1870-8. doi: 10.1007/s00259-014-2776-9. Epub 2014 Apr 30. Eur J Nucl Med Mol Imaging. 2014. PMID: 24781871 - Usefulness of FMISO-PET for glioma analysis.
Kobayashi H, Hirata K, Yamaguchi S, Terasaka S, Shiga T, Houkin K. Kobayashi H, et al. Neurol Med Chir (Tokyo). 2013;53(11):773-8. doi: 10.2176/nmc.ra2013-0256. Epub 2013 Oct 29. Neurol Med Chir (Tokyo). 2013. PMID: 24172591 Free PMC article. Review. - Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.
Lee ST, Scott AM. Lee ST, et al. Semin Nucl Med. 2007 Nov;37(6):451-61. doi: 10.1053/j.semnuclmed.2007.07.001. Semin Nucl Med. 2007. PMID: 17920352 Review.
Cited by
- Usefulness of positron emission tomographic studies for gliomas.
Miyake K, Ogawa D, Okada M, Hatakeyama T, Tamiya T. Miyake K, et al. Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):396-408. doi: 10.2176/nmc.ra.2015-0305. Epub 2016 May 31. Neurol Med Chir (Tokyo). 2016. PMID: 27250577 Free PMC article. Review. - Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Postema EJ, et al. Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1565-73. doi: 10.1007/s00259-009-1154-5. Epub 2009 May 9. Eur J Nucl Med Mol Imaging. 2009. PMID: 19430784 Clinical Trial. - Novel imaging approaches to head and neck cancer.
Krohn KA, Yeuh B. Krohn KA, et al. Semin Oncol. 2008 Jun;35(3):262-73. doi: 10.1053/j.seminoncol.2008.03.001. Semin Oncol. 2008. PMID: 18544441 Free PMC article. Review. - Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.
Barajas RF Jr, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Barajas RF Jr, et al. Case Rep Radiol. 2015;2015:731361. doi: 10.1155/2015/731361. Epub 2015 Feb 22. Case Rep Radiol. 2015. PMID: 25793136 Free PMC article. - Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.
Waerzeggers Y, Ullrich RT, Monfared P, Viel T, Weckesser M, Stummer W, Schober O, Winkeler A, Jacobs AH. Waerzeggers Y, et al. Br J Radiol. 2011 Dec;84 Spec No 2(Spec Iss 2):S179-95. doi: 10.1259/bjr/76389842. Br J Radiol. 2011. PMID: 22433828 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical